Large Cap Pharma Stock Declares Record Date For Rs 4/Share Dividend

Large cap stock operating in the Pharmaceuticals sector, Lupin Ltd has fixed Friday, July 14, 2023 as the record date for dividend of Rs 4/- per equity share of Rs 2/- each for the year ended March 31, 2023. Lupin shares offered 36% return in last 3-months and 43% return in last 1-year. Check details below:

Lupin Sets Record Date For Dividend: According to the BSE filing of the company, "We wish to state that pursuant to the provisions of Section 91 of the Act read with Rule 12 of the Companies (Management and Administration) Rules, 2014 and Regulation 42 of the Listing Regulations, the Company has fixed Friday, July 14, 2023, as the 'Record Date' for the purpose of ascertaining the shareholders who will be entitled to payment of Dividend if declared at the AGM."

Lupin Dividend: Dividend for the year ended March 31, 2023, @ 200% i.e., a 4/- per equity share of a 2/- each, if declared at the AGM, shall be paid to those Members whose names appear as beneficial owners as at the end of the business day on Friday, July 14, 2023, as per lists to be furnished by National Securities Depositories Limited ('NSDL') and Central Depositories Services (I) Limited ('CDSL'), in respect of shares held in electronic form.

Lupin Stock Performance & Return: Current market price of Lupin share is Rs 896.65 per share with intraday gain of 0.65% on BSE. The stock's 52-week high price is Rs 908.65 per share and 52-week low price is Rs 602.80 per share, respectively. It has a market capitalisation of Rs 40,804.75 crore.

Lupin shares delivered return of 20% in last 6-months, declined 22% in last 2-years, and fell again a little over 2% in last 5-years.

Lupin Financial Performance: The company for the quarter ended March 31, 2023 declared its consolidated total income at Rs 4,467.35 crore, up 2.93% as against Rs 4340.18 crore declared in the corresponding quarter last year. The company announced its net profit after tax at Rs 242.39 crore in the latest quarter.

About Lupin: Lupin is the U.S. wholly-owned subsidiary of Lupin Limited, which is among the top pharmaceutical companies in India. Through its sales and marketing headquarters in Baltimore, MD Lupin is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies, according to its LinkedIn page.

Disclaimer: The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for ay losses. Please consult a professional advisor.